These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 15777218)

  • 41. Enzyme/abzyme prodrug activation systems: potential use in clinical oncology.
    Nishi Y
    Curr Pharm Des; 2003; 9(26):2113-30. PubMed ID: 14529409
    [TBL] [Abstract][Full Text] [Related]  

  • 42. cAMP-mediated regulation of CYP enzymes and its application in chemotherapy.
    Ishikawa Y; Suzuki S; Otsu K; Ulucan C; Iwatsubo K; Eguchi H
    Drug Metab Lett; 2007 Aug; 1(3):176-8. PubMed ID: 19356040
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antibody directed enzyme prodrug therapy (ADEPT) and related approaches for anticancer therapy.
    Jung M
    Mini Rev Med Chem; 2001 Nov; 1(4):399-407. PubMed ID: 12369965
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeted prodrug design to optimize drug delivery.
    Han HK; Amidon GL
    AAPS PharmSci; 2000; 2(1):E6. PubMed ID: 11741222
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potential use of radiolabeled glucuronide prodrugs with auger and/or alpha emitters in combined chemo- and radio-therapy of cancer.
    Unak T
    Curr Pharm Des; 2000 Jul; 6(11):1127-42. PubMed ID: 10903386
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glucuronides in anti-cancer therapy.
    Chen X; Wu B; Wang PG
    Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):139-50. PubMed ID: 12678908
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy.
    Huo M; Zhu Q; Wu Q; Yin T; Wang L; Yin L; Zhou J
    J Pharm Sci; 2015 Jun; 104(6):2018-2028. PubMed ID: 25820241
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives.
    Greco O; Dachs GU
    J Cell Physiol; 2001 Apr; 187(1):22-36. PubMed ID: 11241346
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nanoparticles as delivery carriers for anticancer prodrugs.
    Fang JY; Al-Suwayeh SA
    Expert Opin Drug Deliv; 2012 Jun; 9(6):657-69. PubMed ID: 22507134
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lipid prodrug nanocarriers in cancer therapy.
    Mura S; Bui DT; Couvreur P; Nicolas J
    J Control Release; 2015 Jun; 208():25-41. PubMed ID: 25617724
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor-activated prodrugs--a new approach to cancer therapy.
    Denny WA
    Cancer Invest; 2004; 22(4):604-19. PubMed ID: 15565818
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
    Senter PD; Springer CJ
    Adv Drug Deliv Rev; 2001 Dec; 53(3):247-64. PubMed ID: 11744170
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents.
    Devkota L; Lin CM; Strecker TE; Wang Y; Tidmore JK; Chen Z; Guddneppanavar R; Jelinek CJ; Lopez R; Liu L; Hamel E; Mason RP; Chaplin DJ; Trawick ML; Pinney KG
    Bioorg Med Chem; 2016 Mar; 24(5):938-956. PubMed ID: 26852340
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cancer chemotherapy and drug metabolism.
    Riddick DS; Lee C; Ramji S; Chinje EC; Cowen RL; Williams KJ; Patterson AV; Stratford IJ; Morrow CS; Townsend AJ; Jounaidi Y; Chen CS; Su T; Lu H; Schwartz PS; Waxman DJ
    Drug Metab Dispos; 2005 Aug; 33(8):1083-96. PubMed ID: 16049130
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Designing anticancer multitarget metal thiosemicarbazone prodrug based on the nature of binding sites of human serum albumin carrier.
    Yang F; Liang H
    Future Med Chem; 2018 Aug; 10(16):1881-1883. PubMed ID: 29925269
    [No Abstract]   [Full Text] [Related]  

  • 56. Prodrugs for improving tumor targetability and efficiency.
    Mahato R; Tai W; Cheng K
    Adv Drug Deliv Rev; 2011 Jul; 63(8):659-70. PubMed ID: 21333700
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Toxicity mechanism-based prodrugs: glutathione-dependent bioactivation as a strategy for anticancer prodrug design.
    Zhang XY; Elfarra AA
    Expert Opin Drug Discov; 2018 Sep; 13(9):815-824. PubMed ID: 30101640
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prodrug-activating systems in suicide gene therapy.
    Springer CJ; Niculescu-Duvaz I
    J Clin Invest; 2000 May; 105(9):1161-7. PubMed ID: 10791987
    [No Abstract]   [Full Text] [Related]  

  • 59. Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.
    Prosser GA; Copp JN; Mowday AM; Guise CP; Syddall SP; Williams EM; Horvat CN; Swe PM; Ashoorzadeh A; Denny WA; Smaill JB; Patterson AV; Ackerley DF
    Biochem Pharmacol; 2013 Apr; 85(8):1091-103. PubMed ID: 23399641
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular mechanisms of bufadienolides and their novel strategies for cancer treatment.
    Deng LJ; Li Y; Qi M; Liu JS; Wang S; Hu LJ; Lei YH; Jiang RW; Chen WM; Qi Q; Tian HY; Han WL; Wu BJ; Chen JX; Ye WC; Zhang DM
    Eur J Pharmacol; 2020 Nov; 887():173379. PubMed ID: 32758567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.